Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Oral Deucravacitinib for the Treatment of Nail Psoriasis
NCT05124080Phase 1Completed
- Sponsor
- University of Alabama at Birmingham
- Start
- Mar 2024
- Primary completion
- Dec 2025
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of deucravacitinib in nail psoriasis and plaque psoriasis, sponsored by University of Alabama at Birmingham. Primary endpoint: modified Nail Psoriasis Severity Index at 24 weeks. Started Mar 2024; status: completed.
02
Drugs
deucravacitinib
03
Conditions
nail psoriasisplaque psoriasis
Beyond the preview
Go deeper on NCT05124080.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05124080.